Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance

Overview

• U.S. opioid treatment maker's Q2 revenue rose 14%, beating analyst expectations

• Adjusted EPS for Q2 beat consensus

• Company repurchased $175 mln in shares during Q2

Outlook

• Indivior raised 2026 net revenue guidance to $1.295 bln-$1.365 bln from $1.215 bln-$1.285 bln

• Company now expects 2026 SUBLOCADE net revenue of $1.01 bln-$1.05 bln, up from $950 mln-$990 mln

• Indivior sees 2026 adjusted EBITDA of $700 mln-$740 mln, up from $620 mln-$660 mln

Result Drivers

• SUBLOCADE GROWTH - Co said Q2 revenue growth was driven by a 21% year-over-year rise in SUBLOCADE net revenue, with U.S. SUBLOCADE revenue up 22% on 18% higher dispense unit volume and record new patient starts

• LOWER OPERATING EXPENSES - Co reported a 25% year-over-year decrease in GAAP operating expenses and a 33% decrease in non-GAAP operating expenses in Q2

• FAVORABLE PRICING AND ADJUSTMENTS - Co said net revenue benefited from more favorable price/mix and gross-to-net adjustments

Company press release: ID:nGNX2Lzz2F

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Indivior Pharmaceuticals Inc is $49.00, about 22.5% above its July 31 closing price of $40.01

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads

• July 31 - Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision

• July 31 - AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

• Aug 2 - For GLP-1 users, the in-store clothes shopping trip is back

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)